Anaptys, a leading biotechnology company, announced positive top-line findings from its global Phase 3 trial evaluating imsidolimab's safety and efficacy in patients with generalized pustular psoriasis flares.

Promising Results

The study demonstrated that investigational imsidolimab successfully achieved its primary endpoint in the study population. Following a single 750mg IV dose of imsidolimab, rapid clearance of pustulation, erythema, and scaling was observed.

Favourable Safety Profile

The top-line data also showcased a favorable safety and tolerability profile for imsidolimab. All adverse effects reported in patients treated with imsidolimab were mild or moderate. Moreover, the incidence of adverse effects was similar between imsidolimab-treated patients and those who received a placebo. There were no reports of serious or severe adverse effects in the imsidolimab-treated group.

Future Plans

Anaptys has outlined its plan to present comprehensive data from the trial in the second half of 2024. Additionally, they are preparing to submit a biologics license application to the U.S. Food and Drug Administration by the third quarter of 2024.

Citigroup to Sell China Consumer Wealth Portfolio to HSBC

FDA Rejects Approval Application for Alnylam's Drug, Onpattro

Leave A Reply

Your email address will not be published. Required fields are marked *